Pfizer explores options for some rare disease and cancer drugs

Pfizer is exploring options for some early-stage treatments for rare diseases and cancer in a bid to focus on “high-impact” medicines and vaccines, the company said last week.

The US drugmaker said these options included collaborations with other drug developers for these medicines, or establishing a new company.

Pfizer now plans to focus on internally developing rare disease treatments using technologies such as gene editing, it said, while exploring external opportunities for early-stage gene therapy programmes and its cancer-focussed research facility in Boulder, Colorado.

Edits by EP News Bureau